Hartford Financial Management’s Celldex Therapeutics CLDX Stock Holding History

Hartford Financial Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-18	Closed	-$667	–	387
2024 Q2	$667	Hold	18	–	–	﹤0.01%	378
2024 Q1	$756	Hold	18	–	–	﹤0.01%	376
2023 Q4	$714	Hold	18	–	–	﹤0.01%	385
2023 Q3	$496	Hold	18	–	–	﹤0.01%	386
2023 Q2	$611	Hold	18	–	–	﹤0.01%	365
2023 Q1	$648	Hold	18	–	–	﹤0.01%	373
2022 Q4	$802	Hold	18	–	–	﹤0.01%	366
2022 Q3	$1K	Buy	+18	New	+$552	﹤0.01%	368
2022 Q2	–	Sell	-18	Closed	-$1K	–	387
2022 Q1	$1K	Hold	18	–	–	﹤0.01%	379
2021 Q4	$1K	Hold	18	–	–	﹤0.01%	355
2021 Q3	$1K	Hold	18	–	–	﹤0.01%	386
2021 Q2	$1K	Buy	+18	New	+$494	﹤0.01%	370
2017 Q3	–	Sell	-18	Closed	–	–	389
2017 Q2	$0	Buy	+18	New	+$796	﹤0.01%	369
2017 Q1	–	Sell	-18	Closed	-$1K	–	347
2016 Q4	$1K	Hold	18	–	–	﹤0.01%	310
2016 Q3	$1K	Hold	18	–	–	﹤0.01%	311
2016 Q2	$1K	Hold	18	–	–	﹤0.01%	294
2016 Q1	$1K	Hold	18	–	–	﹤0.01%	294
2015 Q4	$4K	Hold	18	–	–	﹤0.01%	248
2015 Q3	$2K	Hold	18	–	–	﹤0.01%	242
2015 Q2	$6K	Buy	+18	New	+$7.15K	﹤0.01%	231
2015 Q1	–	Sell	-18	Closed	-$4K	–	131
2014 Q4	$4K	Hold	18	–	–	﹤0.01%	231
2014 Q3	$3K	Hold	18	–	–	﹤0.01%	265
2014 Q2	$4K	Hold	18	–	–	﹤0.01%	258
2014 Q1	$4K	Hold	18	–	–	﹤0.01%	237
2013 Q4	$6K	Hold	18	–	–	﹤0.01%	215
2013 Q3	$9K	Hold	18	–	–	0.01%	210
2013 Q2	$4K	Buy	+18	New	+$3.54K	﹤0.01%	241

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Hartford Financial Management's CLDX Position: Q3 2024 in Review

Hartford Financial Management sold out of Celldex Therapeutics (CLDX) in Q3 2024, closing a stake of 18 shares — an estimated $667 sold.

Hartford Financial Management first reported a position in CLDX in Q2 2013 and held it in 27 quarters. The position peaked at $9K in Q3 2013. 176 funds tracked by Wall St. Rank hold CLDX as of Q3 2024.

Hartford Financial Management reported no remaining Celldex Therapeutics position as of Q3 2024 after selling out during the quarter.
Hartford Financial Management sold 18 Celldex Therapeutics shares in Q3 2024, an estimated $667.
Hartford Financial Management first reported a position in Celldex Therapeutics in Q2 2013 and held it in 27 quarters.
Hartford Financial Management's Celldex Therapeutics position peaked at $9K in Q3 2013.
176 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2024.

Based on Hartford Financial Management's 13F filing for Q3 2024, filed 28 Oct 2024.